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KESAN JANGKITAN HEPATITIS DAN HASIL KLINIKAL SERTA TREND 
JANGKA HAYAT DI KALANGAN PESAKIT HIV/AIDS YANG 
MENGAMBIL UBATAN HAART DI HOSPITAL PULAU PINANG 
ABSTRAK 
Literatur yang sedia ada menunjukkan bahawa Hepatitis dengan atau tanpa Virus 
Kurang Daya Tahan (HIV) lazimnya berkongsi cara pemindahan dan masalah 
kesihatan awam yang utama di seluruh dunia. Matlamat kajian ini adalah untuk 
menilai prevalens HBV dan HCV di kalangan pesakit HIV positif, peramal yang 
terlibat dalam hasil klinikal dan trend kemandiran hidup di kalangan pesakit 
jangkitan bersama. Kajian ini termasuk 808 pesakit HIV positif dari unit penyakit 
berjangkit terlibat dalam kajian keratan rentas, retrospektif dari 2007-2012 yang 
dijalankan di Hospital Pulau Pinang (HPP). Data telah dikumpulkan melalui borang 
pengumpulan data yang disahkan.  
Sejumlah 808 pesakit HIV positif telah dipertimbangkan untuk kajian ini dan dari 
jumlah itu, didapati 627 (77.6%) adalah lelaki dan 181 (22.4%) adalah perempuan. 
Kaum Cina merupakan kaum majoriti iaitu 500 (61.9%) pesakit berbanding dengan 
kaum Melayu iaitu 161 (19.9%) pesakit dan kaum India hanya mempunyai 104 
(12.9%) pesakit. Secara keseluruhan, kebanyakan pesakit telah berkahwin dan ini 
merangkumi 380 (47.0%) orang, berumur di bawah 40 tahun iaitu 407 (50.4%) 
orang, perokok sebanyak 457 (56.6%) orang, bukan alkoholik sebanyak 499 (61.8%) 
orang dan penagih dadah bukan intravena pulak sebanyak 680 (84.2%) orang 
merupakan majoriti di kalangan populasi kajian. Cara pemindahan utama yang 
diperhatikan dalam kajian ini adalah melalui hubungan heteroseksual iaitu 572 
(70.8%). Median (julat) kiraan sel CD4, ALT dan ALP populasi kajian ini masing-
masing adalah 461 (11 - 956), 26 (6 - 226) dan 93 (44-495). Semua ubat rejimen 
yang digunakan dalam HAART untuk pesakit HIV adalah dari kumpulan nucleoside 
xv 
 
Reverse transcriptase Perencat (NRTIs) dan Bukan nucleoside Reverse transcriptase 
Perencat (NNRTIs). Tenofovir (TDF) + Emtricitabine (FTC) + Efavirenz (EFV) 
merupakan pilihan gabungan dan diberi majoriti kepada pesakit iaitu 215 (26.6%) 
orang termasuk HIV-virus hepatitis B dan pesakit jangkitan bersama HIV-HCV. 
Dalam populasi kajian ini, didapati Tuberkulosis pulmonari adalah sebanyak 185 
(27.4%), diikuti dengan pneumonia Pneumocystis 116 (17.2%) dan kencing manis 
62 (9.2%). Prevalens keseluruhan HBV di kalangan populasi kajian ini adalah 86 
(13%), termasuk 76 (11.4%) lelaki dan 10 (1.5%) perempuan. Majoritinya adalah 
kaum Cina 64 (9.6%), berumur 40 tahun ke atas sebanyak 48 (7.2%) dan bujang 42 
(6.3%). Peramal yang terlibat dalam hasil klinikal jangkitan bersama HIV-HBV 
adalah jantina perempuan (OR = 2.015; p = 0.007), kumpulan umur > 40 tahun (OR 
= 0,559; p = 0.002), status perkahwinan bercerai (OR = 0.440; p = 0.039) dan bukan 
penagih dadah  intravena (OR = 2,996; p = <0.001). Dalam trend hidup jangkitan 
bersama HIV-HBV, kadar kemandiran hidup didapati lebih tinggi dalam penagih 
dadah bukan intravena (p = 0.035). Didapati prevalens HCV adalah 18.4% di 
kalangan populasi kajian dan ini termasuk 122 (17.2%) lelaki dan 8 (1.1%) 
perempuan. Kaum Melayu 76 (10.7%) adalah majoriti di kalangan pesakit jangkitan 
bersama HIV-HCV diikuti dengan kaum Cina 36 (5.1%) dan India 14 (2.0%). Hasil 
klinikal pesakit jangkitan bersama HIV-HCV mempunyai peramal penting  iaitu 
jantina perempuan (OR = 2.015; p = 0.002), kumpulan umur > 40 tahun (OR = 
0,635; p = 0.007) dan bukan penagih dadah intravena (OR = 2,376; <0.001). Dalam 
trend kemandiran hidup pesakit jangkitan bersama HIV-HCV, didapati pesakit di 
bawah umur 40 tahun (p = 0,028) dan bukan penagih dadah intravena (p = 0.048) 
mempunyai kadar kemandiran yang lebih tinggi. Dalam populasi kajian ini, didapati 
prevalens jangkitan tiga kali ganda (HIV-HBV-HCV) adalah 2.4%.  
xvi 
 
Prevalens keseluruhan HBV adalah lebih rendah berbanding HCV di kalangan 
populasi kajian. Jantina, kumpulan umur dan pengguna dadah secara suntikan adalah 
peramal yang terlibat dalam hasil klinikal pesakit jangkitan bersama HIV-HBV dan 
HIV-HCV. Kadar kemandiran hidup yang lebih tinggi ditemui pada lelaki, penagih 
dadah bukan intravena dan berumur di bawah 40 tahun dalam trend kemandiran 
hidup pesakit jangkitan bersama. 
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IMPACT OF VIRAL HEPATITIS ON CLINICAL OUTCOMES AND 
SURVIVAL TRENDS AMONG HIV/AIDS PATIENTS ON HAART AT 
HOSPITAL PULAU PINANG 
ABSTRACT 
 
The existing literature suggests that Hepatitis with or without Immunodeficiency 
Virus (HIV) shared common routes of transmission and major public health 
problems throughout the world. Aims of the present study are to evaluate the 
prevalence of Hepatitis B (HBV) and Hepatitis C (HCV) among HIV positive 
patients, predictors involved in the clinical outcomes and survival trends among cited 
co-infected patients. The present study includes 808 HIV positive patients from 
infectious disease unit in a retrospective, cross-sectional study from 2007 to 2012 
conducted at Hospital Pulau Pinang (HPP). Data were collected through a validated 
data collection form.  
Out of 808, there were 627 (77.6%) males and 181 (22.4%) were females. Chinese 
accounted for 500 (61.9%) patients in majority as compare to Malays accounted for 
161 (19.9%) patients and Indians for a total of 104 (12.9%) patients. Majority of the 
patients were married 380 (47.0%), below the age of 40 years 407 (50.4%), smokers 
457 (56.6%), non-alcoholic 499 (61.8%) and non-intravenous drug users 680 
(84.2%) among the overall study population. The main route of transmission 
observed in the present study was heterosexual contact 572 (70.8%). The median 
(range) of CD4 cell count was 461 (11 - 956), ALT 26 (6 - 226) and ALP 93 (44 - 
495) of the study population. All the regimens used in HAART for HIV patients 
were from Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) groups. Tenofovir (TDF) + 
Emtricitabine (FTC) + Efavirenz (EFV) were common choice in the majority of the 
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patients (215, 26.6%) including HIV-HBV and HIV-HCV co-infected patients. 
Pulmonary tuberculosis was observed 185 (27.4%) in the study population followed 
by Pneumocystis pneumonia 116 (17.2%) and Diabetes Mellitus 62 (9.2%). The 
overall prevalence of HBV among the study population was 86 (13%) including 76 
(11.4%) males and 10 (1.5%) females. The majority was Chinese race 64 (9.6%), 
above 40 years of age 48 (7.2%) and single 42 (6.3%). Predictors involved in clinical 
outcomes of HIV-HBV co-infected patients were female gender (OR = 2.015; p = 
0.007), >40 years age group (OR = 0.559; p = 0.002), divorced marital status (OR = 
0.440; p = 0.039) and non-intravenous drug users (OR = 2.996; p = <0.001). Higher 
survival rates was found in non-intravenous drug users (p = 0.035) in survival trends 
of HIV-HBV co-infected patients. HCV prevalence was found 18.4% among the 
study population including 122 (17.2%) males and 8 (1.1%) females. Malays 
accounted for 76 (10.7%) patients in majority among HIV-HCV co-infected patients 
followed by Chinese 36(5.1%) and Indians 14 (2.0%). Clinical outcomes of HIV-
HCV co-infected patients have the significant predictors as female gender (OR = 
2.015; p = 0.002), >40 years age group (OR = 0.635; p = 0.007) and non-intravenous 
drug users (OR = 2.376; <0.001). In survival trends of HIV-HCV co-infected 
patients higher survival rates was found in patients below 40 years of age (p = 0.028) 
and non-intravenous drug users (p = 0.048). Prevalence of triple infection (HIV-
HBV-HCV) was found to be 2.4% in the study population. 
The overall prevalence of HBV was lower than HCV among the study population. 
Gender, age groups and intravenous drug users are the predictors involved in the 
clinical outcomes of HIV-HBV and HIV-HCV co-infected patients. Higher survival 
rates were found in males, non-intravenous drug users and below 40 years of age 
patients in survival trends of the co-infected patients. 
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CHAPTER 1 
INTRODUCTION 
 
Human immunodeficiency virus (HIV) is a Ribonucleic acid (RNA) 
retrovirus that destroys and harms the cells of the human immune system by 
impairing their function (WHO, 2007a). Hepatitis B Virus (HBV) is a member of 
hepadnaviridae family and is a small virus having a partially double-stranded 
relaxed, circular DNA genome (Block et al., 2007). Hepatitis C virus (HCV) belongs 
to flaviviridae family and it is hepatotropic RNA virus of the genus Hepacivirus 
(Kim et al., 2013). 
1.1 Human Immunodeficiency Virus (HIV) 
1.1.1 Epidemiology 
In past two decades, human immunodeficiency virus (HIV) has stormed 
across the world. Currently there are about 34 million people living with HIV and the 
death rate of people with AIDS since the starting of the epidemic is nearly 30 million 
(UNAIDS, 2012). However, in the year 2011, about 1.7 million people died of AIDS 
and there is a decrease of 24% since 2005 and of 20 % since 2001 in middle income 
countries while in East Asia there were 5 million people living with HIV. 
Furthermore, the two most populated nations like China and India there are relatively 
low frequency rates of HIV infections even into large numbers of people (UNAIDS, 
2012). Over 20,000 HIV cases have stated since 1980 and half of them have died. In 
December 2011, total 20,091 HIV cases have been stated and among all 34% were 
female and 66% were male throughout the world (Mullen et al., 2013). 
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In the United States, the epidemiology of HIV has transformed pointedly 
from the early 1980s. This disease is presently a disease of demographic variety and 
affecting many factors like genders, races, ages and including several behaviors that 
can transmit the risks of HIV infection and there are at least 50,000 new HIV 
infected cases reported each year and one-fifth of them do not know that they are 
HIV infected which is a alarming scenario (Moore, 2011). The estimated death rate 
of HIV infection is 15,529 people in the year 2010 and overall 636,000 people 
diagnosed with AIDS in the United States (CDC, 2013). 
 
The first case of HIV in Malaysia was in 1986 when a Chinese male of 45 
years old of an American origin was visiting the country and fell ill (UNGASS, 
2010). The World Health Organization reports that Malaysia has been classified as 
“a concentrated epidemic” due to the persistent progression of HIV infection in the 
population of Injecting Drug Users. Moreover, a study showed that if no cautious 
plans and schemes been taken effectively against the increased growth of HIV 
infection, then in the year 2015 up to 300,000 HIV cases would be reported in 
Malaysia (Tham et al., 2012). 
 
1.1.2 HIV Transmission 
HIV transmission at high risk in general population involves several 
transmitting routes like injecting drug users, female sex workers and men who have 
sex with men (Mumtaz et al., 2013). HIV transmission also involves exposure to 
contaminated blood, sexual contact, from mother to child during pregnancy and 
breast milk (Bourinbaiar et al., 1991). 
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In Malaysia the key way of HIV transmission is basically the use and sharing 
of needles by using intravenous drugs and secondly through heterosexual contact 
(Choy et al., 2012). A survey conducted by the Ministry of Health in Malaysia 
showed that there were some delusions about transmission and prevention of 
HIV/AIDS in the country (Aung et al., 2013). 
 
1.1.3 Pathogenesis 
HIV infection involves a single target cell infected with single virion entering 
the host cell.  The ensuing course of infection can be examined in various ways like 
monitoring the symptoms such as adaptable infection, fever, blood levels of targeted 
cells and so on usually measured by PCR for viral RNA (Coffin et al., 2013). 
 
The pore formation is basically the actual fusion that takes place within 
minutes and with the help of reverse transcriptase enzyme the genome is reverse 
transcribed just after the core is disassembled. During this process various viral 
variants can be produced until the enzyme has no proof reading activity. As the 
molecules in the cytoplasm of the producer’s cells and components of the cell 
surface that is actually a lipid bilayer are combined with new viral particle, the 
virions adapt the characteristics of the cells in which they were produced. The host 
cell molecules can determine the virus’ phenotype in different ways like shape and 
replicative features in the next infection cycle (Simon et al., 2006). 
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1.2 Hepatitis B Virus (HBV) 
1.2.1 Epidemiology 
 
The World Health Organization estimates that about 2 billion of the 
worldwide population exposed to HBV infection and 450 million people are infected 
chronically. While the occurrence of HBV infection is 45 % of the world population 
that includes Moldova as well and the rate of HBeAg detection is 8% and greater in 
the infected publics (Iarovoi et al., 2008). The worldwide epidemiology of HBV 
shows that the number of HBV infected people is 360 million with chronic infection 
and the death rate is of HBV related diseases is 600,000 (Shepard et al., 2006). 
 
Some studies estimated that 350 million carriers having chronic infections of 
HBV are present globally and its occurrence varies in different regions showing 
various frequencies like from high (more than 8%), intermediate (2 to 7%) and low 
(less than 2 %) (Hou et al., 2005). In common population the incidence of chronic 
HBV infection in Ireland and the Netherlands is ranges from 0.2% to 7 % (Hatzakis 
et al., 2011). Hepatitis B virus infection is widespread in Asia with 50 % infected 
population and shows its high progression in China, Hong Kong and Malaysia 
(Kawsar et al., 2002). 
 
1.2.2 Transmission 
 
The transmission route of HBV is sexual and percutaneous just like HIV so 
both have common routes of transmission (Thio, 2009). The two main routes of 
transmission of HBV are sharing needles and homosexuality (Sheng et al., 2004). 
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According to the World Health Organization, the HBV transmission modes 
are through blood or body fluids of an infected person just like the transmission of 
HIV. Furthermore, there are several ways for HBV transmission like sexual contact, 
perinatal, mother to child and through insecure use of injections and transfusions 
(WHO, 2014). 
 
1.2.3 Pathogenesis 
HBV is a kind of noncytopathic virus and there are various factors that 
influencing the pathogenesis of  HBV including its co-infection with other viruses 
most particularly of HIV and Hepatitis C (HCV) while there is a difference between 
the controlling of patients infected with dual viruses and patients infected with a 
single virus (Cheruvu et al., 2007). There are eight genotypes of HBV from (A-H) 
varying geographically and have impact on disease progression and outcomes of 
treatment and the disease expressions during chronic HBV infection depend on the 
balance between the virus and immune responses of the host (Puoti et al., 2006). 
 
1.3 Human Immunodeficiency Virus and Hepatitis B Virus Co-infection 
Studies reported that about 10% of HIV infected patients are co-infected with 
chronic HBV although the occurrence of HIV-HBV co-infection differs globally 
(Kellerman et al., 2003; Uneke et al., 2005). There are more than 350 million 
individuals having HBV infection chronically worldwide (WHO, 2007) and nearly 
33 million people are HIV infected (UNAIDS, 2008). In United States the estimated 
rate of HIV infected individuals is 1.25 million (Te et al., 2010). There are higher 
rates of co-infection detected in the areas having common prevalence of chronic 
HBV infection like in Asia and Sub Saharan Africa (Uneke et al., 2005). Chronic 
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HBV infection in the United States is not common and the rate of this infection is 
greater among the adults having intravenous and sexual transmission routes (Brito et 
al., 2008). It is estimated that 10 % persons of HIV infected patients out of 40 
million are co-infected with chronic HBV throughout the world (Thio, 2009). 
 
In HIV co-infected patients, the progression of hepatitis B is categorized 
through the increased frequency of active viral replication. There is a continuous 
reduction in CD4 cell counts as certainly the viral replication is enhanced and linked 
to reduced cellular immune response in contrast of HBV in the progression of 
untreated HIV infection. Furthermore, there is a reduction in inflammation reaction 
and normal or slightly levels of liver enzymes are elevated in response to weak 
immune response (Boesecke et al., 2010). 
 
HIV and HBV have shared mode of transmission so their co-infection is very 
common (Thomas et al., 1994). In HBV infected individuals the treatment outcome 
of HIV-1 infection is not understood properly. Some studies reported that there is a 
reduction in the development of liver disease and might be predictable since the 
pathogenesis of HBV infection is supposed to be mediated immunologically (Thio et 
al., 2002; Webster et al., 2000). 
 
In HIV infected patients, the HBV infection is considered as opportunistic 
infection and this co-infection can cause severe interactions because HIV weakens 
the cellular immunity following a greater replication of HBV infection increases 
replication of HIV by stimulation of transcriptional factor and inflammatory 
cytokines (Sheng et al., 2004). 
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In the United States and Western Europe, the infection of HBV is 
acknowledged in 5 to 16 % of the persons infected with HIV (Alter, 2006; Thio, 
2003). Co-infection of HIV and HBV enhanced the risk of liver-related morbidity. 
However, HIV induced the weakening of innate and adaptive immunity so lower 
occurrences of natural loss of HBV surface antigen (HBsAg) have been observed 
(Kim et al., 2012). Natural history of hepatitis B virus changes by the co-infection of 
HIV-1 with higher serum HBV DNA and lower levels of alanine aminotransferase 
(ALT) leading the increased rates of cirrhosis predominantly in those individuals 
with low CD4 T cell counts (Lewin et al., 2009). 
 
The levels of viral replication in chronic hepatitis B virus carriers relates with 
the existence of detectable antigen of HBV in serum. In the reported studies related 
to co-infection of HIV with HBV carriers the frequency of loss of HBeAg positivity 
determined the natural history of HBV replication. In HBV carriers among HIV 
infected persons there is a lower rate of tendency has been reported. In a study 
another measure of viral replication in the lowering rate of detectable HBV DNA in 
serum was found to be considerably reduced in HIV-infected HBV carriers (Gilson 
et al., 1997). 
 
The HBV and HIV co-infection enhances the mortality as well as morbidity 
in comparison with those caused by other mono infections (Hoffmann et al., 2007). 
There are higher levels of hepatitis B viremia in individuals co-infected with HIV. 
Moreover, approximately five times fast progression to hepatitis B infection, 
hepatocellular carcinoma and cirrhosis in patients with HIV as compare to 
individuals infected with only hepatitis B virus (Kourtis et al., 2012). 
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1.4 Hepatitis C Virus (HCV) 
1.4.1 Epidemiology 
It is estimated that 130 million people are infected with HCV globally. In 
addition, the occurrence of HCV is about 27% of cirrhosis and 25% of 
Hepatocellular carcinoma (HCC) worldwide (Alter, 2007). Both the temporal and 
geographic differences are there in the trends of HCV infections. Overall general 
average prevalences (1.0%-1.9%), of HCV infections have been seen in various 
countries like United States (Alter, 2002), Spain (Domínguez et al., 2001), Australia 
(Dore et al., 2003), Italy (Sagnelli et al., 2005) and Japan (Sun et al., 2001). The 
reported rate of high prevalence (15%-20%) of HCV infection is in Egypt 
(Abdel‐Aziz et al., 2000)  and lowest widespread (0.01%-0.1%) is in the Scandinavia 
and the United Kingdom (Frank et al., 2000; Shepard et al., 2005). Globally it is 
estimated that about 150 million people are infected with HCV and about 350,000 
deaths occur due to HCV (Zidan et al., 2012). 
1.4.2 Transmission 
The main mode of HCV transmission is repetitive percutaneous exposure to 
blood through injecting drug use and transplantation or transfusion from infected 
donors. A less active mode of HCV transmission is through mucosal contacts to 
serum-derived fluids (e.g. sexual contact with an infected partner) or blood and by 
needle sticks (Alter, 2007). The main route of childhood HCV transmission is from 
mother to infant and this transmission is ranges from 3% to 10%. The transmission 
risk is high among the women at delivery and HIV co-infected (Cottrell et al., 2013). 
About 20 % of HCV infections are not explained particularly in non-injecting drug 
users (Aaron et al., 2008). About 20 % of patients with HCV denied the common 
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risk factors like intravenous drug use and other exposures although the main route of 
transmission for HCV infection was intravenous drug use (Tohme et al., 2012). 
 
1.4.3 Pathogenesis  
There are several diseases related with HCV infection like hepatocellular 
carcinoma, fibrosis and autoimmune diseases and considering the immune responses 
from other members of the Flaviviridae family. HCV is classified as a member of a 
genus Hepacivirus based on the similar patterns of hydrophobicity and homology 
(Chambers et al., 1990; Houghton et al., 1991). After the prime infection of 
flavivirus the persistent infection is infrequent in addition with HCV. The previous 
trends of chronic HCV infection are those with prolonged lobular inflammation and 
portal tracts of changing severity. The composition of infiltrate is primarily CD8+ T 
cells (Marrogi et al., 1995). In chronic HCV hepatitis there is an acidophilic 
degeneration inside the intact plates and formation of apoptotic bodies shown by 
hepatocytes. Proliferation and damage to the bile duct may also happen. Hepatitis C 
virus can act with iron to stimulate liver damage (Freeman et al., 2001). 
1.5 Human Immunodeficiency Virus and Hepatitis C Co-Infection 
Globally estimated rate of infections caused by Hepatitis C was 130 million 
with an overall prevalence of 3% and about 4 to 5 million people are co-infected 
with HIV. Moreover, the prevalence of HCV among injection drug users (IDU) is 
about 72% to 95 %, 1% to 12% in MSM (in men who have sex with men) and 9% to 
27% in heterosexuals among HIV infected persons in the US and Western countries 
(Alter, 2006). There are 15 to 45 % persons clear the HCV virus after acute infection 
and the rate of individuals is 20% to 30% with persistent viremia develop liver 
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fibrosis, and potentially cirrhosis, following liver failure, and hepatocellular 
carcinoma (Operskalski et al., 2011). 
 
The occurrence of HCV co-infection in individuals infected with HIV is high 
and ranges from 10 to 40%, and can be increased up to 80 % in highly exposed 
regions (Cohen, 1999; Greub et al., 2000). Both the HIV and HCV are having shared 
transmission routes particularly through injection drug use and the receipt of blood 
transfusions or products so there is a high association in HIV and HCV co-infection. 
Furthermore, in AIDS defining events there found an increased  progression of death 
rates in co-infected patients with HCV (Anderson et al., 2004). 
  
It is reported in most studies that HIV has adverse effects on natural history 
of hepatitis C virus infection and there is an association between HIV infection with 
higher HCV viral loads, hepatitis B virus persistence and increased risk of end stage 
liver disease (ESLD) in most studies (Bica et al., 2001; Martín-Carbonero et al., 
2001; Thomas et al., 2000). The levels of HCV-RNA become higher after co-
infection with HIV. Literature shows that in HIV infected patients the HCV-RNA 
levels are higher with lower CD4+ counts than 200/mm
3
as compared to patients 
infected with HIV having higher CD4+ counts (Thomas, 2005; Thomas et al., 1996). 
 
The infection of hepatitis C virus is frequently prevalent in the population of 
HIV infected individuals with one third of Americans infected with HIV and 
worldwide 7 million are being co-infected (Soriano et al., 2010). Now the leading 
cause of death is chronic HCV infection after the complications associated with 
AIDS among the individual of HIV infection in the regions where highly active 
antiretroviral therapy (HAART) is available (Taylor et al., 2012). 
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HIV-HCV co-infected individuals have numerous consequences for clinical 
administration and care; First of all there is a high viral load of HCV in HIV co-
infected individuals. Secondly the risk of hepato-toxicity increases with hepatitis C 
virus under ART, predominantly with drugs like, nevirapine and can affect the 
choice of timing and therapy. Thirdly, there might be precipitation in Hepatitis C 
virus immune reconstitution occurrences by the use of HAART in HCV infected 
persons, and may also be reduced immune recovery in co-infected individuals (Yami 
et al., 2011). 
 
In HIV-HCV co-infected patients, there is a reduction in HCV specific T-cell 
responses, an outcome consistent with a higher rate of development to chronicity in 
these patients (Rehermann, 2007). The responses of T-cell in chronic hepatitis C are 
usually weak. There is weaker CD4
+
 and CD8
+
 responses seem in co-infected 
patients and even after CD4 cell counts recover in response to HAART, these 
responses are not restored (Rotman et al., 2009).  
 
 On the pathogenesis of hepatitis C virus infection the effects of HIV-1 are 
harmful and contain a higher rate of viral persistence and hepatic decompensation, 
increased rates of viral loads and a faster rate of fibrosis progression (Kim et al., 
2009). 
 
 Literature shows that there are higher levels of HCV in the blood of HIV 
infected patients following a rapid progression to liver diseases related to hepatitis C 
virus and higher risk of liver disease and cirrhosis. In addition, HCV is now 
considered as adaptable infection in HIV infected people (Martín-Carbonero et al., 
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2001). Strader (2005) reported that in HIV-HCV positive patients, an increased 
progression in liver diseases related to hepatitis C virus and the effect of HCV on the 
development of HIV infection seems to be minimal to modest. 
 
1.6 Highly Active Antiretroviral Therapy (HAART) 
The name given to the insistent treatment regimens used to stop the 
development of HIV disease and to suppress replication of HIV virus is Highly 
Active Antiretroviral Therapy (HAART). According to WHO, antiretroviral therapy 
course of action, lower CD4 count or below 350 cell/mm
3 
in all HIV infected patients 
should be started on ART (WHO, 2010a). The area of HIV medicine is continuously 
changing and developing. The improvements made in more than last two decades 
have reformed. All the medication and preventive cares necessary for antiretroviral 
therapy are not available in all regions (Samuel et al., 2006).  
Antiretroviral drugs were introduced Malaysia in different stages; in 1989 
zidovudine was available followed by didanosine and zalcitabine in early 1990s and 
stavudine and lamivudine in mid 1990s and HAART drugs were available in 2006 in 
Malaysia and are of three types named as NRTI, NNRTI and PI (Shah et al., 2012). 
There were three specific drugs authorized as “government use order” providing to 
all government hospitals were didanosine, zidovudine and the combination of 
lamivudine and zidovudine since 2004 (UNGASS, 2010). On the basis of patient-
centered outcomes highly active antiretroviral therapy has been seemed to be cost 
effective (Montaner et al., 2006). 
 
Modifications in the treatment of HIV infection, predominantly in the 
HAART have very much decrease mortality and enhanced the quality of life for a 
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number of HIV/AIDS positive individuals. In addition, several studies in the recent 
years reported their concern on the factors related with the non-adherence to HAART 
and also examined the procedures of predicting medication adherence noticeably less 
consideration has been dedicated to how adherence changes over time (Carrieri et al., 
2001; Howard et al., 2002; Levine et al., 2005). 
 
About 10 % of the patients experience a drug related liver injury after the 
initiation of HAART with an increase level of liver transaminases up to five times 
than the normal limit (Vogel et al., 2007). Luckily, most of the elevations of liver 
transminases are only temporary and rarely direct to clinically severe symptoms or 
the termination of HAART . There is an increase risk of HAART related toxicity in 
the patients co-infected with HCV therefore, if possible then antiretroviral drugs like 
stavudine, didanosine and full-dose ritonavir with high risk of hepatotoxicity should 
be avoided (Qurishi et al., 2003). In general the significance of HAART is far 
compensating the risk of hepatotoxicity. This is possibly on account of immune 
reconstitution of highly active antiretroviral therapy (Vogel et al., 2008). 
 
It has been always challenging to decide that when to start treatment in an 
HIV-infected individual. On the other hand, initiation of treatment should be started 
at any beginning point of the course of disease, earlier to a time when loss of CD4 
cells is such that there is a considerable risk of clinical development (Clumeck et al., 
2008). Evidence suggest there were low clinical progression rates although the CD4 
cell count remained more than 200 cells/μl but also increased quickly at lower levels, 
strategies of most initial treatment suggested that there would be delayed in treatment 
until the CD4 cell count had fallen below 200 cells/μl (Sabin et al., 2009). 
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The majority of doctors trained in treating HIV in Malaysia considering the 
antiretroviral (ARV) strategies released by WHO which suggested that all patients 
start antiretroviral therapy when their CD4 count lower to 200 cells/ mm3 or lower, 
at which position many previously show symptoms of HIV disease and other 
opportunistic infections. Moreover, the usual ART treatment of choice at present 
practiced in Malaysia comprises of the combination of two nucleoside reverse-
transcriptase inhibitors (NRTIs), in general either zidovudine (AZT) + lamivudine 
(3TC) or stavudine (d4T) + 3TC with a nonnucleoside reverse-transcriptase inhibitor 
(NNRTI), normally either nevirapine (NVP) or efavirenz (EFV ). However, a generic 
combination of triple drug which is extensively accessible and of low cost called 
SLN (stavudine + lamivudine + nevirapine) (WHO, 2010b). 
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1.7 Problem Statement 
 
For over years, people all over the world have debated about the association 
between human immunodeficiency virus and chronic viral hepatitis. Patients with 
human immunodeficiency virus can be under a great risk to develop viral hepatitis 
especially in those with lowered CD4 counts. Therefore, the ignorance of this 
problem may lead to serious health complications with increased risk of mortality 
rate in human immunodeficiency virus infected population. All these factors prompt 
the efforts to investigate the prevalence of Hepatitis B and C among HIV/AIDS 
patients, associated risk factors involved in the clinical outcomes and survival trends 
of HIV-HBV and HIV-HCV co-infected Malaysian population. 
 
1.8 Rationale of the Study 
 
The link between human immunodeficiency virus and chronic viral hepatitis 
is considered controversial, therefore, many questions to be addressed related to this 
association. Best to researcher’s knowledge there is no published data that 
investigate the association between human immunodeficiency virus and chronic viral 
hepatitis (B and C) in Malaysia. Furthermore, internationally very limited data is 
available on survival trend among HIV/AIDS patients with viral hepatitis co-
infection. Based on this information, the current study is aimed to evaluate the 
epidemiological connection between human immunodeficiency virus and chronic 
hepatitis (B and C) among the Malaysian population. Moreover, present study 
investigates the associated factors involved in the clinical outcomes and survival 
trends of HIV-HBV and HIV-HCV co-infected patients which are being treated with 
HAART.  
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1.9 Significance of the Study 
 
The results of the current study provide the baseline data for future studies 
that focused on the association between the human immunodeficiency virus and 
chronic viral hepatitis. Moreover, current study may support the background of 
practitioners about the possibility of developing chronic viral hepatitis especially 
hepatitis C among the human immunodeficiency virus infected population. It could 
also help to reduce the hepatitis occurrence in human immunodeficiency virus 
infected patients by attracting the attention of the involved risk factors and to avoid 
the clinical complications of HIV and Hepatitis association. On the other hand, 
present study also gives an idea for HIV infected patients and possible risk factors 
involved in the clinical outcomes and survival trends of the patients due to these 
combinations.  
 
1.10 Study Objectives 
 
1) To determine the prevalence of hepatitis B among HIV population of the 
study 
2) To evaluate the prevalence of hepatitis C among HIV infected population of 
the study 
3) To determine factors that involved in the clinical outcomes of the study 
population. 
4) To evaluate the survival trend among HIV/AIDS and Hepatitis co-infected 
population. 
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CHAPTER 2 
LITERATURE REVIEW 
 
Following chapter aims to shed light on previously conducted studies, on prevalence 
of Hepatitis B and C among HIV/AIDS patients; predictors involved in the clinical 
outcomes of HIV-HBV and HIV-HCV co-infected patients and survival trends of 
HIV-HBV and HIV-HCV co-infected patients. 
2.1 Prevalence of Viral Hepatitis among HIV infected individuals 
 
Mohammadi et al. (2009) conducted a descriptive, cross-sectional study from 
January 2007 to January 2008 in Iran reported the prevalence of HBV and HCV 
among the HIV positive patients. In that study 391 HIV positive individuals were 
included in which 358 were males and 33 were females. The prevalence of HBV was 
observed in 57 (14.5%) and HCV in 282 (72%) of the total study population. Study 
concluded that 72% of the patients were HIV-HCV co-infected and 14.5% patients 
were co-infected with HIV-HBV. A significant correlation was seen in the co-
infected patients depending on different variables which include age, sex, marital 
status, occupation, exposure. 
 
An epidemiological study conducted in Zambia by Kapembwa et al. (2011) 
to assess the prevalence of HBV and HCV among HIV infected patients. Researcher 
included 323 HIV infected patients in a tertiary care hospital of Lusaka, Zambia. 
Demographic, medical and laboratory data was collected to determine the risk factors 
of co-infection. Out of 323 HIV infected patients 32 (9.9%) were co-infected with 
HBV and 4 (1.2%) co-infected with HCV. Patients with hepatitis B co-infection were 
more likely to be <40 years (84.4% vs. 61.4%; P = 0.01) as compared to HIV mono 
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infected patients. Mild to moderately increased AST/ALT (40-199 IU/L, 15.8% vs. 
5.4%; P = 0.003) was observed in patients co-infected with active hepatitis B. Risk 
factors associated with HCV co-infection was not determined in this study due to 
low prevalence of disease. Study concluded that the regular screening of HIV 
infected patients for hepatitis B virus in southern Africa. 
 
 A study in Gambia to determine the seroprevalence of HBV and HCV in 
HIV-infected subjects as the prevalence of HIV-Hepatitis co-infection is not well 
documented in sub-Saharan Africa. A total of 190 individuals with AIDS and 382 
without AIDS patients were tested retrospectively for the presence of HBV and HCV 
co-infection. The prevalence of HBV in HIV-positive subjects was 12.2%. The CD4 
count <200cells/µL had higher HBV DNA viral load as compared to higher CD4 
count (log 4.0 vs. log 2.0 DNA copies/ml, p < 0.05) in HIV-HBV co-infected 
individuals. Seroprevalence of HCV was 0.9% among HIV-infected patients. The 
prevalence of HBV carriers in general population is similar to the HIV infected 
Gambians while HIV-HBV co-infected population had lower CD4 count and 
elevated liver enzymes as compared to the general population (Jobarteh et al., 2010). 
 
Yanagimoto et al. (2012) conducted a retrospective multicentre analysis in 
Japan reported that 6% of HIV infected individuals were co-infected with hepatitis B 
after that they included 252 patients infected with HIV from six hospitals of Japan. 
The main route of transmission was observed in homosexual contact followed by 
heterosexual contact [186 of 252; (74%)], the mean age of patients was 39.5 ± 9.6 
years and the proportion of males was very high as compared to females [243 of 252; 
96%)]. Advance liver disease with the complication of ascites, hepatocellular 
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carcinoma and hepatic encephalopathy developed in three patients among 252 HIV-
HBV co-infected patients. A comparison between treated patients with antiretroviral 
treatment along with anti-HBV drugs and untreated patients the liver function was 
worse in the patients who were treated than untreated however, platelet counts and 
albumin levels were similar observed in both groups. Study concluded that the 
antiretroviral treatment along with anti-HBV drugs in HIV-HBV co-infected patients 
may retard the progression of the disease and prevent liver related death in such co-
infected patients. 
 
The prevalence of HBV co-infection in HIV positive individuals and its 
impact on all-cause deaths, progression of disease, liver related deaths and its 
response towards antiretroviral treatment was assessed by Konopnicki et al. (2005). 
Data was collected from 72 European HIV centers included 9802 patients. Global 
mortality and liver-related mortality, incidence of AIDS, time to viral load <400 
copies/ml and time to 25% CD4 cell count increase after initiation of the HAART 
treatment and then compared between HBsAg negative and positive individuals. 
Total 498 (8.7%) patients were found to be HBeAg positive. The incidence rate of 
newly diagnosed AIDS patients was similar in HBeAg negative and positive patients 
(3.4 and 3.3/100 person-year respectively). The incidences of liver related and all-
cause morbidities were significantly greater in HBeAg positive patients (0.7 and 
3.7/100 person-years respectively) as compared to HBeAg negative patients (0.2 and 
2.6/100 person-years respectively). In 1679 patients HBeAg status did not influence 
immunological or viral responses after the initiation of HAART. The study 
concluded that the prevalence of HBV among HIV individuals was 9% and chronic 
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infection of HBV significantly increases liver-related mortality in HIV-1 infected 
population. 
 
A cross-sectional study was conducted to evaluate the prevalence of HBV in 
HIV infected patients and impact of antiretroviral therapy in Thailand. A total of 403 
individuals were enrolled with mean age of 42.3 years and 60.3% were male. HBV 
co-infection was observed in 33(8.2%) patients with median (IQR) CD4 cell count of 
395 (277-555) cells/mm
3
. The patients receiving ART had the prevalence of HBV 
6.1% and the prevalence without ART was 11.4%. The AST levels before the 
initiation of ART (OR = 1.020, 95% CI (1.007-1.034); p = 0.003) and undetectable 
HIV RNA at the time of screening (OR = 0.243, 95% CI (0.068-0.870); p = 0.030) 
were significantly associated with the HBV co-infection. HBV co-infection was not 
significantly associated with the liver enzymes. The study concluded that the 
screening of HBV among HIV individuals should not be omitted and screening 
should be performed before the initiation of the ART (Chotiprasitsakul et al., 2010). 
 
Adewole et al. (2009) carried out a study in National hospital in Abuja, 
Nigeria to evaluate seroprevalence of hepatitis B and hepatitis C among HIV infected 
patients and its impact on pattern of presentation. Total 260 HIV positive patients 
were enrolled in the study to figure out the prevalence of HBV and HCV. Patients 
were co-infected with HBV were 30 (11.5%) while 6 (2.3%) were co-infected with 
HCV however, only 4 (1.5%) were triple infected observed in the study and the 
overall prevalence of viral hepatitis among HIV positive patients was 15.4%. 
Patients younger than 40 years of age were more affected in study and the odd ratios 
for females being co-infected was 1.2 (25% Vs 75%) with the p value of 0.03. There 
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was no significant difference in the mean levels of liver enzymes (ALT, AST) among 
the difference cohorts. In co-infected groups the mean CD4 count was 
(106cells/mm
3
) significantly differs as compared to the HIV mono-infected patients 
(171cells/mm
3
).  The highest value of CD4 count (260cells/mm
3
) was observed in 
HIV-HCV co-infected patient. Adewole concludes that the HIV-HCV prevalence 
may be due to intravenous drug abusers and HIV-HBV co-infection was common in 
present study which should be under major consideration before the starting and 
choice of therapy. 
 
Anbazhagan et al. (2010), carried out a study in south Tamil Nadu, India to 
evaluate the seroprevalence of HCV among HBV, hepatitis delta virus (HDV) and 
HIV positive patients. Among 1012 samples, 512 were clinically diagnosed with 
liver diseases and 500 were apparently healthy individuals were enrolled for HCV 
screening. The seroprevalence of HCV among study population was found to be 29 
(5.6%). Co-infection of HCV-HBV, HCV-HIV, HCV-HBV-HIV were found in 8, 6 
and 4 patients respectively. The majority of the patients were males in HCV-HBV 
co-infection and females were in the majority in HCV-HIV and HIV-HBV-HCV co-
infections. The mean AST and ALT levels in HCV positive patients were 49 ± 10.1 
and 42.1 ± 8.3 IU/L respectively. In HCV-HBV, HCV-HIV, HCV-HBV-HIV co-
infected patients the mean ALT level was 58.0 ± 03.16, 56.78 ± 4.401 and 64.37 ± 
4.01 IU/L respectively. Study concludes that the routine screening of HCV should be 
done in addition to HIV and HBV and regular surveillance to monitor and prevent 
these types of blood-borne viruses. 
Seyed Alinaghi et al. (2011) conducted a study in Iran during 2004-2005 to 
determine the seroprevalence of HBV and HCV among HIV infected individuals. A 
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total of 201 blood samples were taken from HIV positive patients to evaluate the 
prevalence of HBV and HCV. 27 (13.4%) patients were HBsAg positive, 60 (29.8%) 
were anti-HBc positive and anti-HBs was observed in 23 (11.4%) patients. Anti-
HCV Ab positive patients were 135 (67.2%). The majority of HIV-HBV and HIV-
HCV co-infected patients were intravenous drug users; 61.2% and 85.1% 
respectively (p<0.0001). The minimum prevalence of both HBV and HCV among 
the study population were observed in HIV patients wife’s (8%) (p<0.0001). Present 
study concluded that the co-infections with HBV and HCV were significant with the 
HIV/AIDS in Iran and suggested to evaluate the risk factors involved in these co-
infections. 
 
Reuter et al. (2011), established a prospective study to evaluate the 
prevalence and characteristics of hepatitis B and C among HIV positive treatment-
naïve individuals. A total of 918 patients were enrolled in the study from RESINA-
cohort, Germany. All clinical parameters and blood samples were taken prior to start 
the antiretroviral therapy. HBV, HBsAg and HBV DNA were found in 43.4% 
(398/918), 4.5% (41/918) and 6.1% (34/554) patients respectively. HCV positive 
patients were 10.6% (97/918) in the study. HCV positivity was associated with non-
African ethnicity, IVDU route of transmission, abnormal liver enzymes elevation and 
low viral load of HIV. Both HBV and HCV correlated with HIV resistance mutations 
(p = 0.001 and p = 0.028). Study concludes that the prevalence of HBV and HCV 
among HIV treatment-naïve patients was very high. Moreover, the patients should be 
routinely screened for HBV and HCV before the initiation of HIV treatment. HIV 
resistance mutations were significantly associated with the HBV and HCV positive 
status. 
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2.2 Clinical outcomes of HIV and viral hepatitis co-infected patients 
  
 Zhou et al. (2007) established a study in the Asia-Pacific region to determine 
the prevalence of HBV and HCV, their impact on antiretroviral therapy and rate of 
mortality among the HIV positive individuals using the data from The TREAT Asia 
HIV Observational Database (TAHOD). Among 2979 TAHOD patients, the overall 
prevalence of HBV and HCV both was approximately 10%. After initiation of 
antiretroviral therapy the mean CD4 count after 180 days was118.8cells/µL while the 
patients co-infected with either HBV or HCV had lower but non-significant increase 
in the CD4 count as compared to HIV mono infected patients. Median time was 148 
days to reach undetectable viral load (<400 copies/mL) and was not associated with 
either HBV or HCV. The patients co-infected with HCV had increased mortality 
(unadjusted hazard ratio, HR 2.80, P=0.007) using univariate analysis. However, 
there was no association between HBV and HCV with the increase in the mortality 
rate. In the multivariate model both HBV and HCV showed independently associated 
with the increase in the level of Alanine transaminase (ALT). The study concluded 
that the impact of hepatitis on virological and immunological responses and disease 
progression among this Asian cohort are similar to that reported in the western 
countries. Morbidity and mortality needs to be monitored among these co-infected 
patients. 
  
A study was conducted in central Italian prisoners by La Torre et al. (2007) 
from the period of 1995 to 2000 to determine HIV, HBV and HCV co-infection 
determinants. HIV-HBV, HIV-HCV and HBV/HCV co-infections were observed in 
31 (2.9%), 42 (4%) and 203 (17.9%) inmates, respectively. These co-infections were 
significantly associated with the smoking habits (OR = 3.73; p = 0.033; OR = 1.42; p 
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= 0.088; OR = 4.25; p = 0.053), status of drug addiction (OR = 16.02; p = 0.012; OR 
= 4.15; p < 0.001; OR = 23.57; p = 0.002) and Italian nationality (OR = 7.05; p = 
0.009; OR = 2.31; p <0.001; OR = 4.61; p = 0.04). Informational and educational 
programs for inmates reduce the prevalence of such infections in jails. 
  
 Mendes-Correa et al. (2011) established a study in Brazil to evaluate the 
clinical and virological variables associated with HBV viremia and HBeAg status in 
HIV-HBV co-infected patients. A retrospective cross-sectional study was conducted 
in two outpatient clinics located in Sao Paulo, Brazil included HIV-HBV co-infected 
patients which were under treatment between 1994 to 2007. Total 86 HIV-HBV co-
infected patients were included in study and among those 48 (56%) were on 
combination therapy included tenofovir (TDF) and lamivudine (LAM). HBeAg 
positive patients were 42 (48.9%) and 44 (51.1%) HBeAg negative. TDF treatment 
longer than 12 months was associated with undetectable HBV DNA viral load (p = 
0.047) assessed by multivariate analysis. 
 
 Thibault et al. (2013) conducted a multicenter cross-sectional study in 19 
French University hospitals from January to December 2007. HBV load, genotype, 
epidemiological and clinical variables of 223 patients co-infected with HIV-HBV 
were investigated. The mean age of patients was 42 years and mostly was male 82%. 
Genotype division (A 52%, E 23.3%, D 16.1%) was associated with geographic 
origin, risk factors and co-infection with other hepatitis viruses. High proportion of 
patients (74.7%) under antiretroviral treatment was receiving a drug that had anti-
HBV activity, including 47% receiving tenofovir (TDF). Advanced liver disease was 
